Leading international law firm Clifford Chance is advising private equity firm Ardian on the strategic acquisition by its investee company, The Dedalus Group, of DXC Technology’s (DXC: NYSE) healthcare software provider business for US$525 million.
The Dedalus Group is one of the world’s leading healthcare and diagnostic software companies, and its combination with the business acquired from DXC aims to expand its operations in hospital information systems, primary and social care, integrated care and diagnostics. The transaction is expected to close by March 2021 subject to satisfaction of customary closing conditions and the receipt of certain third-party consents and regulatory approvals.
The Firm’s cross-border, multidisciplinary team is led out of New York by corporate partner Kevin Lehpamer and includes associates Neil Barlow, Katerina Papacosma and Eric Schaffer and out of Milan by corporate partner Paolo Sersale and includes counsel Filippo Isacco, associates Elisa Ielpo and Mariasole Rinciari. The wider deal team includes partner Charles Adams and associates David Neu and Francesco De Micheli (Finance) in Milan, counsel Daryl Fairbairn and associate Jennifer Saionz (IP/IT) in New York, partner Philip Wagman and associate Sean Smestad (Tax) in New York, partner Chinwe Odimba-Chapman and associate Alistair Green (Employment), partner Sarah McAleer and associate Matthew Preston (Pensions), and partner Andrew Patterson (Incentives) in London and partner Luciano Di Via and associate Antonio Mirabile (Antitrust/Regulatory) in Rome and Brussels.
